Clinical Study

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1A (Rebif®) In Patients With Relapsing Multiple Sclerosis

Posted Date: Sep 9, 2017

  • Investigator: Joseph Nicolas
  • Co-Investigator: Melissa Kahler
  • Specialties: Multiple Sclerosis, Neurology
  • Type of Study: Drug

This study is being conducted by F. Hoffmann-La Roche Ltd. (Roche) and Genentech Inc, called “Sponsor” later on in this document. We want to confirm whether patients treated with ocrelizumab may experience even fewer clinical relapses (also called clinic

Criteria:

• You Must Be 18 To 55 Years Of Age. • You Must Pass The Screening Medical Examinations And Tests (Including A Pregnancy Test For Females Who Are Able To Become Pregnant During The Study); If You Or Your Female Partner (If You Are Male) Are Able To Becom

Keywords:

Relapsing-Remitting, Opera, Ocrelizumab, Multiple Sclerosis, Null

For More Information:

Alecia Boehl
513-558-0039
alecia.boehl@uc.edu

  • Search Clinical Studies

  • Research in the News

    Ride Cincinnati Gives $200,000 in Grants for Breast Cancer Research

    Marlene Harris-Ride Cincinnati has continued its support of UC Cancer Institutescientists with the annual award of five grants to continue promising breastcancer research.